Obesity-related inflammatory protein signature in cardiovascular clinical outcomes: results from the Gutenberg Health Study.

Autor: Panova-Noeva M; Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.; Center for Thrombosis and Haemostasis, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany., Koeck T; Preventive Cardiology and Preventive Medicine, Center for Cardiology, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany.; German Centre for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Mainz, Germany., Schoelch C; Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany., Schulz A; Preventive Cardiology and Preventive Medicine, Center for Cardiology, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany., Prochaska JH; Center for Thrombosis and Haemostasis, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany.; Preventive Cardiology and Preventive Medicine, Center for Cardiology, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany.; German Centre for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Mainz, Germany., Michal M; German Centre for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Mainz, Germany.; Department of Psychosomatic Medicine and Psychotherapy, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany., Strauch K; Institute for Medical Biometrics, Epidemiology and Informatics (IMBEI), University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany., Schuster AK; Department of Ophthalmology, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany., Lackner KJ; German Centre for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Mainz, Germany.; Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany., Münzel T; Center for Thrombosis and Haemostasis, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany.; German Centre for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Mainz, Germany.; Department of Cardiology-Cardiology I, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany., Hennige AM; Therapeutic Area CardioMetabolism & Respiratory, Boehringer Ingelheim International GmbH, Biberach, Germany., Wild PS; Center for Thrombosis and Haemostasis, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany.; Preventive Cardiology and Preventive Medicine, Center for Cardiology, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany.; German Centre for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Mainz, Germany.; Institute of Molecular Biology (IMB), Mainz, Germany.
Jazyk: angličtina
Zdroj: Obesity (Silver Spring, Md.) [Obesity (Silver Spring)] 2024 Jun; Vol. 32 (6), pp. 1198-1209. Date of Electronic Publication: 2024 Apr 25.
DOI: 10.1002/oby.24014
Abstrakt: Objective: The objective of this study was to investigate whether an obesity-related inflammatory protein signature (OIPS) is associated with adverse cardiovascular events.
Methods: The Olink Target 96 Inflammation panel was performed in 6662 participants from the population-based Gutenberg Health Study (GHS). The OIPS was selected by a logistic regression model, and its association with cardiovascular outcomes was evaluated by Cox regression analysis. The GHS-derived OIPS was externally validated in the MyoVasc study.
Results: The identified OIPS entailed 21 proteins involved in chemokine activity, tumor necrosis factor (TNF) receptor binding, and growth factor receptor binding. The signature revealed a novel positive association of axis inhibition protein 1 with obesity. The OIPS was associated with increased risk of all-cause and cardiac deaths, major adverse cardiovascular events, and incident coronary artery disease, independent of clinical covariates and established risk instruments. A BMI-stratified analysis confirmed the association of OIPS with increased death in those with obesity and overweight and with increased risk for coronary artery disease in those with obesity. The association of OIPS with increased risk of all-cause and cardiac deaths was validated in the MyoVasc cohort.
Conclusions: The OIPS showed a significant association with adverse clinical outcomes, particularly in those with overweight and obesity, and represents a promising tool for identifying patients at higher risk for worse cardiovascular outcomes.
(© 2024 The Authors. Obesity published by Wiley Periodicals LLC on behalf of The Obesity Society.)
Databáze: MEDLINE